Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 426-040-2 | CAS number: 25713-60-4 SR-245
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
The absorption, distribution, metabolism and excretion of14C-FR-245 have been studied after a single oral application to rats at concentrations of 50mg/kg/day and 1000mg/kg/day.
Absorption and Excretion: The radioactivity was entirely excreted via the faeces (95.4-105%) with the majority excreted within the interval 0-48 hours. Only very low amounts of radioactivity were found in the urine (0.2%), expired air (<0.1%), carcass (<0.01% low dose; 0.03-1.27% high dose) and cage washes (0.01-0.26%). Total absorption was therefore, 0.2% of the administered dose. No biliary excretion was considered to have occurred since the majority of faecal radioactivity was recovered within a short time period (0-48 hours) and was mainly unmetabolised parent compound. Thus, there was no significant additional contribution from entero-hepatic recirculation via the bile to the overall absorption for this compound.
Distribution: The proportion of the absorbed dose in all tissues, carcasses and including blood at the time of the peak plasma concentration (4 hours) was only 0.3%. This reduced to 0.2-0.3% after 24 hours and to < 0.01-0.02% after 168 hours. The maximum proportion of the dose in whole blood was only 0.05-0.07% indicating there was minimal absorption into the blood stream and re-circulation back to the intestine via bile.
At 4 hour sampling the highest levels were detected in liver and kidney with all other tissues concentrations representing less than 151 ng equivalents/g. At 24 hour sampling the highest levels were detected in liver, kidney, epididymis, ovaries and uterus with all other tissue concentrations less than 86.1 ng equivalent/g.After 168 hours the highest concentrations were detected in epididymis, fat and kidney with all other tissue representing less than 14.5ng equivalent/g.
Metabolites: The majority (81.3-93.2%) of the excreted radioactivity over 0-48 hours was confirmed by analysis to be unmetabolised FR-245 parent test substance. Several unknown components were detected none of which represented greater than 2/6% of the dose. The minor components detected (total of <9.1%) are most likely formed as a results of the aggressive action of both gastric and intestinal secretions, including various enzymes, on FR-245 molecules during transit through the gastro-intestinal tract.
Based on the experimental results it can be concluded that FR-245 is not likely to accumulate in biological tissues.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
